Monitoring Agency Report for the Quarter- IV of financial year 2025-26 ended March 31, 2026.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Orchid Pharma has submitted the Q4 monitoring report for its Rs. 400 crore Qualified Institutions Placement (QIP), monitored by CARE Ratings. The report confirms no deviation from stated objects and nil deviation range. However, the company revised QIP fund allocation among objects with shareholder approval obtained via AGM on September 20, 2025. The Alathur API facility received Rs. 36 lakhs (fully utilized by June 2025). The Jammu manufacturing facility (Orchid Bio Pharma Ltd) faces significant delays due to land acquisition challenges with farmers; commercial operations are now expected by February 2027. Rs. 3.77 crore has been spent on technical know-how. The company shifted more allocation towards Jammu facility and repayment of credit limits while reducing allocation to Alathur API facility.
Shareholders should note the Jammu project is delayed by over a year from original plans due to land acquisition hurdles, though management assures construction is in advanced stage. The shareholder-approved reallocation of QIP proceeds is being implemented as per revised schedule.